An update to the agency's adverse event reporting system cited the risk of suicidal ideation; alopecia, or hair loss; and inhalation of stomach contents is connected to drugs treating diabetes and weight loss that include Wegovy, Ozempic, Mounjaro and Zepbound.
Demand for the drugs - part of a class known as GLP-1 agonists - has exploded, even while experts note there isn't enough data about the long-term effects and how they work in certain populations.
[
add
]
[
|
|
...
]